Tessa Therapeutics picks Wilson W. Cheung as CFO

Singapore-based Tessa Therapeutics has announced the appointment of Wilson W. Cheung as its Chief Financial Officer (CFO). Cheung brings to Tessa more than 25 years of experience in accounting and corporate finance, compliance, and corporate leadership at both public and private companies with presence in both the US and China. He joins Tessa as the company is advancing the clinical exploration of its autologous CD30-CAR-T therapy (TT11) and its allogeneic CD30.CAR EBVST therapy (TT11X) programs. As CFO, Cheung will lead Tessa’s overall fiscal management, as well as the company’s investor relations, and business development strategy. He will initially operate in the US before relocating to Tessa’s global headquarters in Singapore. Prior to Tessa, Cheung served as EVP and CFO at Apollomics Inc. where he led the efforts to complete a $124 million Series C round. Prior to Apollomics, he was the CFO at KBP Biosciences, Inc. and served as SVP and CFO at SciClone Pharmaceuticals, Inc. where he led the sale of SciClone to a private equity firm for more than $600 million. Before SciClone, Cheung worked for Velti Plc as CFO and was responsible for leading the company’s US IPO and a follow-on offering that raised more than $340 million.